title: Trial design in psoriatic arthritis: what could be changed?
abstract: A greater understanding of the underlying disease process, combined with the development of novel therapeutic agents, has led to innovative strategies in the treatment of psoriatic arthritis (PsA). This report addresses unmet needs in clinical trial design in PsA, and proposes some amendments that may yield data that can potentially improve patient outcomes in the management of PsA.
authors.affiliation: Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, CA, USA. akavanaugh@ucsd.edu.
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.affiliation: Division of Rheumatology, University of California, La Jolla, CA, USA.
authors.forename: Tristan
authors.initials: T
authors.lastname: Boyd
mesh_terms: D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods*; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D023381:Endpoint Determination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012074:Remission Induction; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents